Clinical trial · no report yet · Phase 2
RAMP 201
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
- NCT04625270 ↗
- Active not recruiting
- Verastem, Inc.
- 38 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 18 | |
| Podcasts | 11 | |
| X threads | 9 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Low Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer
- Interventions
- avutometinib (VS-6766); avutometinib (VS-6766) and defactinib
- Arms
- Part A · Experimental
- Part B · Experimental
- Part C: · Experimental
- Part D · Experimental
- Enrollment
- 225 (estimated)
- Primary outcomes
- Part A: Determine optimal regimen of avutometinib (VS-6766) monotherapy or in combination with defactinib
- Part B: To determine the efficacy of the optimal regimen identified from Part A
- Part C: To evaluate additional efficacy parameters for the optimal regimen identified in Part A
- Part D:To evaluate additional efficacy parameters for a lower dose of avutometinib in combination with defactinib
- Sponsor
- Verastem, Inc. with European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
- Start
- Dec 21, 2020
- Primary completion
- Nov 15, 2024
- Results posted
- No
- Registry record
- NCT04625270 · updated Jan 29, 2025
Publications
linked from the registry- Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, Prendergast E, Oaknin A, Ring K, Colombo N, Holloway RW, Rodrigues M, Chon HS, Gourley C, Santin AD, Thaker PH, Gennigens C, Newman G, Salinas E, Youssoufian H, Moore KN, Lustgarten S, O'Malley DM, Van Gorp T, Grisham RN. Efficacy and Safety of Avutometinib +/- Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol. 2025 Sep;43(25):2782-2792. doi: 10.1200/JCO-25-00112. Epub 2025 Jul 11. PubMed 40644648
- McNamara B, Demirkiran C, Hartwich TMP, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz PE, Coma S, Pachter JA, Santin AD. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecol Oncol. 2024 Apr;183:133-140. doi: 10.1016/j.ygyno.2024.01.028. Epub 2024 Mar 15. PubMed 38493021